Journal
STEM CELL RESEARCH
Volume 35, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.scr.2019.101405
Keywords
-
Funding
- Czech Science Foundation [15-11707S, 15-28628A]
- National Program of Sustainability II (MEYS CR) [LQ1605]
- National Program of Sustainability I [L01304]
- MEYS CR [RVO: 61989592, LM2015062 Czech-BioImaging]
- Masaryk University [MUNI/C/1418/2017]
- DRO (FNOl) from the Czech Ministry of Health [00098892]
Ask authors/readers for more resources
Human induced pluripotent stem cell line was generated from commercially available primary human prostate fibroblasts HPrF derived from a fetus, aged 18-24 weeks of gestation. The fibroblast cell line was reprogrammed with Yamanaka factors (OCT4, SOX2, c-MYC, KLF4) using CytoTune (TM)-iPS 2.0 Sendai Reprogramming Kit. Pluripotency of the derived transgene-free iPS cell line was confirmed both in vitro by detecting the expression of factors of pluripotency on a single-cell level, and in vivo using teratoma formation assay. This iPS cell line will be a useful tool for studying both normal prostate development and prostate cancer disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
